Colorectal cancer. Neoplasms,Digestive organs
Conditions
Interventions
Intervention 1: In supplemented group,patients will consume four 1000 mg capsules daily (providing 3 gr CLA ) for 6 weeks .Patients are instructed to take once at each of 3 mealtimes and once before
Prevention
Placebo
In supplemented group,patients will consume four 1000 mg capsules daily (providing 3 gr CLA ) for 6 weeks .Patients are instructed to take once at each of 3 mealtimes and once before bedtime. The su
In placebo group,patients will consume four placebo capsules daily for 6 weeks . Patients are instructed to take once at each of 3 mealtimes and once before bedtime. The intervention begins 1 week b
Sponsors
Nutritional Research Center,Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients with colorectal cancer in stage II and III undergoing preoperative radiotherapy combined with chemotherapy Exclusion criteria: renal and liver disease; diabetes mellitus; thyroid disorders; consumption of vitamin or mineral supplements; under weight(BMI<18.5); previous radiotherapy; history of other cancers and patients with clinical evidence of metastatic disease.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum conjugated linoleic acid. Timepoint: Before radiotherpay and at the end of intervention(6 weeks). Method of measurement: Gas Chromatography.;Inflammatory factors(TNF-a, IL-1, IL-6, hs-CRP). Timepoint: Before radiotherpay and at the end of intervention(6 weeks). Method of measurement: Elisa kit, hs-CRP: kit immunoturbidimetry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight,. Timepoint: Before radiotherapy and at the end of intervention(6 weeks). Method of measurement: Weight:Scale.;Eating problem symptoms. Timepoint: Before radiotherapy and at the end of intervention(6 weeks). Method of measurement: Eating problem symptoms questionnaire.;Dietary inake of patients. Timepoint: Before radiotherapy and at the end of intervention(6 weeks). Method of measurement: 24 hour food recall questionnaire.;TAS, MDA, Albumin. Timepoint: Before radiotherapy and at the end of intervention(6 weeks). Method of measurement: TAS, Albumin kit, MDA fluorimetry.;MMP-2, 9. Timepoint: Before radiotherapy and at the end of intervention(6 weeks). Method of measurement: MMP-2,9:kit.;Liver enzymes ,Tumor marker (CEA). Timepoint: Before radiotherapy and at the end of intervention(6 weeks). Method of measurement: Liver enzymes ,Tumor marker(CEA):kit.;Nutritional status. Timepoint: Before radiotherapy and at the end of intervention. Method of measurement: PG-SGA questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Reza Mahdavi
Facualty of Health and Nutrition
Outcome results
None listed